NCT06629688Completed
Semaglutide and Intestinal Iron Absorption
The Effect of Parenterally Administred Semaglutide on Intestinal Iron Absorption in Individuals With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 5 Dec 2024
Brief summary (registry, in English)
Semaglutide belongs to a group of long-acting glucagon-like peptide 1 receptor agonists (GLP-1). Disorders in iron absorption have been linked to numerous medication, dietary, and nutrient interactions thus far. The study aimed to determine whether there is an effect of concomitant parenteral administration of semaglutide and oral iron preparations on iron absorption in patients with type 2 diabetes (T2DM).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 51 (actual)
- First submitted
- 2 Oct 2024
- Start date
- 1 Nov 2023
- Primary completion date
- 1 Apr 2024
- Lead sponsor
- University Hospital Dubrava
- Diseases
- Type 2 diabetes
- NCT number
- NCT06629688
What you commit to
- Study type: Interventional
- Participants enrolled: 51
- From 1 Nov 2023 to the primary completion date, 1 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- already treated with GLP-1 RA,
- medications that interfere with absorption,
Other illness
- hypersensitivity to GLP-1 RAs,
- type 1 diabetes mellitus or any other form of diabetes,
- severe chronic illnesses,
- malignant neoplasms of any site,
- chronic infectious diseases,
- chronic rheumatic inflammatory diseases,
- malabsorption syndrome,
- inflammatory bowel disease,
- history of gastrointestinal tract reduction surgery,
Lab values
- adequately controlled with current glucose-lowering medications,
Other
- hemochromatosis,
- iron deficiency anaemia,
- sideropaenia,
- perimenopausal women
Who the study is looking for
- T2DM patients
- ages between 45 and 65
- with poorly managed T2DM (HbA1c ≥ 7%)
- who are candidates for treatment intensification and beginning of parenterally administered semaglutide
Age in the registry: 45 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Dubrava Coordinator of this site? Confirm its status | Zagreb | Croatia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.